In a new report, Wedbush analyst Liana Moussatos breaks down potential 2016 catalysts for every emerging pharmaceuticals stock under the firm’s coverage. Overall, Wedbush is very bullish about these 11 Outperform-rated stocks headed into 2016.
Carbylan Therapeutics Inc CBYL 5.21%
Wedbush expects approval of Hydros-TA by early 2018 and a launch by mid-2018. The firm projects peak sales of Hydros-TA for treatment of osteoarthritis pain of the knee of $770 million by 2023 and has a $21 price target on the stock.
Catabasis Pharmaceuticals Inc CATB 4.61%
Wedbush is confident in the company’s management and predicts “blockbuster sales potentials for Catabasis’ clinical candidates due to oral delivery, competitive clinical proficles and premium pricing for orphan drugs.” The firm has a $27 price target for the stock.
Related Link: 5 ‘Bold’ Predictions For 2016
Intercept Pharmaceuticals Inc ICPT 2.81%
Wedbush believes Intercept’s intellectual property in bile acid chemistry gives the stock an attractive risk/reward profile based on the likelihood of clinical success and relatively low regulatory and commercial risk. The firm has a $493 price target for the stock.
Lexicon Pharmaceuticals, Inc. LXRX 4.78%
Moussatos explained, “With at least two potentially significant drug candidates in late-stage clinical development and the ability to refill their pipeline from a drug discovery platform which integrates in-house medicinal chemistry and proprietary gene knockout platforms, we see significant potential upside for the stock.” Wedbush has a $26 target for Lexicon.
Omeros Corporation OMER 9.37%
Wedbush likes…
Click here to continue reading
Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!
